Unlocking Scalability: Innovative Advances in Adherent Manufacturing for Gene Therapies
- Exploring how an innovative, validated process leveraging fixed-bed bioreactors with the option to integrate perfusion technology is advancing adherent manufacturing for gene therapies
- Gaining deeper insights into cell line kinetics and optimizing viability, health, and harvest timing – a level of process control often difficult to achieve with traditional suspension batch methods
- Discovering how this approach translates into cleaner upstream material, higher product volumes, and improved full capsid percentages for AAV viral vectors
- Learning how these advancements enable faster development, more efficient manufacturing, and higher quality products, ultimately accelerating market access for gene therapies, particularly for rare diseases